Warner-lambert Company

Warner-dambert Company LLC

Simon Andrew Osborne

David Christopher Horwell

Justin Stephen Bryans

David Clive Blakemore

Jean-Marie Receveur

William Howson

The compounds of the instant invention are bicyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

Bicyclic amino acids as pharmaceutical agents

The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.

Certain benzofuranyl-N-[pyrrolidin-1-YL]-N-methyl-acetamide derivatives

Peripherally selective kappa opioid agonists

The compounds of the instant invention are ligands for the NK.sub.2 receptor. The compounds are modified at the C-terminus to provide various amide isostere derivatives expected to be useful in treating obesity, anxiety, gastrointestinal ulcers, pain, stroke, and inflammation. Pharmaceutical compositions and methods of using the compounds are also included.

Tachykinin (NK.sub.2) antagonists

Growing community of inventors

Suffolk, United Kingdom

Simon Andrew Osborne